OrthogenRx, Inc. is a late stage development company based on the business strategy of licensing ex-U.S. approved products that are indistinguishable from U.S. approved products and taking advantage of an accelerated regulatory approval process. We commercialize these lower cost products utilizing a…
OrthogenRx, Inc. is a late stage development company based on the business strategy of licensing ex-U.S. approved products that are indistinguishable from U.S. approved products and taking advantage of an accelerated regulatory approval process. We commercialize these lower cost products utilizing a more efficient distribution and reimbursement process to deliver equivalent quality care at significantly reduced costs to insurers and patients. The Company’s initial focus has been on the approval of ‘equivalents’ of intra-articular hyaluronic acid (“HA”) products used in the treatment of osteoarthritis (“OA”) knee pain, a $1 billion dollar market in 2015. The first product, GenVisc 850® (sodium hyaluronate) was approved in September 2015, just 20 months from Seed funding, compared to the industry standard of 6-8 year and $70 million - $100 million development cost. GenVisc 850® was also assigned a unique reimbursement code by the Centers for Medicare and Medicaid Services (CMS) and is positioned to capture a significant share of the HA market. A rich pipeline of follow-on products will allow OrthogenRx to capture a significant share of the estimated $1 billion U.S. market.
Recently, OrthogenRx secured a $2.5 million royalty based line of credit and accordingly is positioned to launch their first product GenVisc 850 late in the first quarter of 2016. We are seeking additional capital of up to $3 million through an exempt offering to optimize the launch of GenVisc 850® in 2016; (ii) accelerate the development of the Company’s product pipeline with FDA filings in 2016 and 2017; and (iii) general working capital and expenses associated with these activities.
Team (1)
Sectors OrthogenRx, Inc serves:
Health Care
Life Sciences
Join Axial's Private M&A Platform
OrthogenRx, Inc connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
